Breakthrough Aging Study Unlocks Peak Performance Secrets
A neuroimaging study in older adults reported measurable upregulation of cholinergic activity following a course of BrainHQ cognitive training,...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy manufacturing compliance Oncology Trials Opinion Parkinson's Disease Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
A neuroimaging study in older adults reported measurable upregulation of cholinergic activity following a course of BrainHQ cognitive training,...
First patient dosed in ACCEL, a 700‑patient, 26‑week, randomized, double‑blind, placebo‑controlled Phase 3 trial assessing twice‑daily tenapanor (IBSRELA) in...
In this in-depth Q&A, we sit with Andrew Mackinnon to explore Medable’s agentic AI platform and its first agents...
Updated Phase 2 data point to a 74% progression-free survival rate at 16 months for iSCIB1+ added to ipilimumab...
A Grade 4 spike in liver transaminases with increased total bilirubin that triggered FDA clinical holds in October 2025...
Belite Bio’s tinlarebant previously delivered a 36% reduction in lesion growth versus placebo (p=0.0033) in the pivotal Phase 3...
BriaCell reported a 52% one-year and 32% two-year survival rate in a Phase 2 cohort of heavily pretreated metastatic...
Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in...
Why competitive insight in the earliest stages of developing a therapy can determine ultimate success By Alex Angelopoulos, Life...
The University of Virginia has opened a first-in-human program for hCitH3-mAb, a monoclonal antibody intended to neutralize citrullinated histone...